{"nctId":"NCT02134210","briefTitle":"Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)","startDateStruct":{"date":"2014-06-16","type":"ACTUAL"},"conditions":["Plaque Psoriasis"],"count":521,"armGroups":[{"label":"Enbrel (etanercept)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Etanercept"]},{"label":"CHS-0214","type":"EXPERIMENTAL","interventionNames":["Drug: CHS-0214"]}],"interventions":[{"name":"Etanercept","otherNames":["Enbrel","European Enbrel"]},{"name":"CHS-0214","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female adults\n* PsO diagnosis for 6 months\n* Active disease: PASI greater than or equal to 12, Physician's Static Global Assessment (PSGA) score greater than or equal to 3 (based on a scale or 0-5),\n* Body Surface Area (BSA) involved with PsO greater than or equal to 10%\n* Dermatology Life Quality Index (DQLI) greater than or equal to 10\n* Previously received phototherapy or systemic non-biologic therapy for PsO\n\nExclusion Criteria:\n\n* Forms of Psoriasis other than PsO\n* Drug induced Psoriasis\n* Positive QuantiFERON-tuberculosis (TB) Gold Test\n* Presence of significant comorbid conditions\n* Chemistry and hematology values outside protocol specified range\n* Major systemic infections","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Proportion of Subjects Achieving PASI-75(75% Improvement in Psoriasis Area and Severity Index) From Baseline at Week 12","description":"The Psoriasis Area and Severity Index (PASI) is well established in the medical literature and is internationally the most widely used instrument to assess the severity of Psoriasis.\n\nProportion of subjects achieving PASI-75 from baseline at Week 12. This was the primary endpoint supporting a Biologics Licensing Application in the US.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"142","spread":null},{"groupId":"OG001","value":"147","spread":null}]}]}]},{"type":"PRIMARY","title":"Mean Percent Change in PASI (Psoriasis Area and Severity Index) at 12 Weeks","description":"Mean percent changed in PASI from baseline (last non-missing value prior to first dose) at Week 12. This was the primary endpoint supporting the Marketing Authorization Application in the EU.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-73.4","spread":"25.0"},{"groupId":"OG001","value":"-76.7","spread":"21.1"}]}]}]},{"type":"SECONDARY","title":"Mean Percent Change in PASI (Psoriasis Area and Severity Index) From Baseline","description":"Mean percent change in PASI from baseline at Weeks 4, 8, 12, 24, 36, and 48","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-42.1","spread":"24.93"},{"groupId":"OG001","value":"-43.2","spread":"22.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-62.8","spread":"24.23"},{"groupId":"OG001","value":"-65.7","spread":"22.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-76.0","spread":"21.96"},{"groupId":"OG001","value":"-77.0","spread":"20.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-83.3","spread":"17.5"},{"groupId":"OG001","value":"-80.8","spread":"20.43"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-82.8","spread":"20.44"},{"groupId":"OG001","value":"-81.9","spread":"18.55"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.9","spread":"18.55"},{"groupId":"OG001","value":"-80.9","spread":"25.08"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Achieved PASI - 75 (75% Improvement in Psoriasis Area and Severity Index)","description":"The proportion of subjects who achieved PASI-75 (75% Improvement in Psoriasis Area and Severity Index) from baseline at Weeks 4, 8, 12, 24, 36, and 48.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"221","spread":null},{"groupId":"OG001","value":"228","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"213","spread":null},{"groupId":"OG001","value":"225","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"213","spread":null},{"groupId":"OG001","value":"225","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"204","spread":null},{"groupId":"OG001","value":"221","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"195","spread":null},{"groupId":"OG001","value":"211","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"178","spread":null},{"groupId":"OG001","value":"203","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Subjects Who Achieved a 50% Improvement in Psoriasis Area and Severity Index (PASI-50) and a 90% Improvement in PASI (PASI-90)","description":"The proportion of subjects who achieved a 50% improvement in Psoriasis Area and Severity Index (PASI-50) and a 90% improvement in PASI (PASI-90) response rates from baseline at Weeks 4, 8, 12, 24, 36, and 48","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86","spread":null},{"groupId":"OG001","value":"89","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"155","spread":null},{"groupId":"OG001","value":"173","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"184","spread":null},{"groupId":"OG001","value":"200","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"69","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"194","spread":null},{"groupId":"OG001","value":"201","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null},{"groupId":"OG001","value":"99","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"183","spread":null},{"groupId":"OG001","value":"197","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"92","spread":null},{"groupId":"OG001","value":"93","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"169","spread":null},{"groupId":"OG001","value":"189","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"91","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in PSGA (Physician's Static Global Assessment) of Disease Activity on a Scale of 0 to 5","description":"Change in PSGA (Physician's Static Global Assessment) of disease activity on a scale of 0 to 5 from baseline to Weeks 4, 8, 12, 24, 36, and 48.\n\nMinimum Value: 0 Maximum Value: 5\n\nThe PSGA of PsO (Psoriasis) was assessed on a scale of 0 to 5, with 0 indicating no PsO (clear of disease),1 (almost clear), and 2 or higher scores indicating more severe disease. Subjects with a clear (0) or almost clear (1) evaluation were considered PSGA responders.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"0.83"},{"groupId":"OG001","value":"-1.2","spread":"0.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.8","spread":"0.94"},{"groupId":"OG001","value":"-1.17","spread":"0.88"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.1","spread":"1.05"},{"groupId":"OG001","value":"-2.1","spread":"0.97"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":"1.5"},{"groupId":"OG001","value":"-2.2","spread":"1.07"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.2","spread":"1.17"},{"groupId":"OG001","value":"-2.1","spread":"1.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.1","spread":"1.11"},{"groupId":"OG001","value":"-2.1","spread":"1.15"}]}]}]},{"type":"SECONDARY","title":"The Proportion of Subjects With a Change in a PSGA (Physician's Static Global Assessment) Score = 0 to 1","description":"The proportion of subjects with a change in a PSGA (Physician's Static Global Assessment) score = 0 to 1, demonstrating clear or almost clear skin at Weeks 4, 8, 12, 24, 36, and 48;\n\nMinimum: 0 Maximum: 1 Subjects with a clear(0) or almost clear(1) evaluation were considered PSGA responders.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.1","spread":null},{"groupId":"OG001","value":"17.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.3","spread":null},{"groupId":"OG001","value":"43.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.1","spread":null},{"groupId":"OG001","value":"60.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.4","spread":null},{"groupId":"OG001","value":"64.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64.6","spread":null},{"groupId":"OG001","value":"60.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.4","spread":null},{"groupId":"OG001","value":"65.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Subject's Global Assessment (SGA) of PsO","description":"Change in Subject's Global Assessment (SGA) of PsO from baseline to Weeks 4, 8, 12, 24, 36, and 48. The SGA of PsO was assessed using VAS (visual analog scale in the unit of millimeters) , ranging from 0 (good) to 100 (severe). The SGA was assessed at randomization (Week 0/Day 0) and Weeks 4, 8, 12, 24, 36, and 48, as well as at the Follow-up Visit, if applicable. The change in SGA is the value at baseline minus sum of values at weeks 4, 8, 12, 24, 36, and 48. Since the change in SGA is measured from baseline, a negative value indicates a decrease in overall SGA and better overall assessment of PsO.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.0","spread":"25.11"},{"groupId":"OG001","value":"-24.0","spread":"22.59"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-37.1","spread":"25.97"},{"groupId":"OG001","value":"-35.0","spread":"25.15"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-45.7","spread":"25.62"},{"groupId":"OG001","value":"-45.1","spread":"27.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-50.1","spread":"28.50"},{"groupId":"OG001","value":"-47.2","spread":"28.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-46.9","spread":"29.23"},{"groupId":"OG001","value":"-47.4","spread":"29.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-50.0","spread":"28.29"},{"groupId":"OG001","value":"-48.7","spread":"30.12"}]}]}]},{"type":"SECONDARY","title":"Change in DLQI (Dermatology Life Quality Index)","description":"Change in DLQI (Dermatology Life Quality Index) from baseline to Weeks 12, 24, and 48\n\nThe DLQI is a 10-question validated questionnaire that was performed at screening, randomization (Week 0/Day 0), and Weeks 12, 24, and 48. It was calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life was impaired.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17.9","spread":"5.7"},{"groupId":"OG001","value":"18.6","spread":"5.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-12.7","spread":"6.2"},{"groupId":"OG001","value":"-13.4","spread":"7.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.3","spread":"6.24"},{"groupId":"OG001","value":"-14.4","spread":"6.85"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.9","spread":"6.32"},{"groupId":"OG001","value":"-14.3","spread":"6.81"}]}]}]},{"type":"SECONDARY","title":"Change in EuroQol 5-Dimension Health Status Questionnaire (EQ-5D)","description":"Change in EuroQol 5-Dimension Health Status Questionnaire (EQ-5D) from baseline to Weeks 12, 24, and 48\n\nThe EQ-5D was performed at randomization (Week 0/Day 0), and Weeks 12, 24, and 48. The EQ-5D is a generic (non-disease specific), preference-based health-related quality of life measure based on 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Rated level can be coded as a number 1, 2, or 3, which indicates having no problems for 1, having some problems for 2, and having extreme problems for 3. As a result, a person's health status can be defined by a 5-digit number, ranging from 11111 (having no problems in all dimensions) to 33333 (having extreme problems in all dimensions).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.81"},{"groupId":"OG001","value":"-0.3","spread":"0.83"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"0.70"},{"groupId":"OG001","value":"-0.3","spread":"0.73"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"0.94"},{"groupId":"OG001","value":"-0.4","spread":"0.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"1.12"},{"groupId":"OG001","value":"-0.9","spread":"1.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"1.01"},{"groupId":"OG001","value":"-0.7","spread":"1.01"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.93"},{"groupId":"OG001","value":"-0.3","spread":"0.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.2","spread":"0.70"},{"groupId":"OG001","value":"-0.3","spread":"0.75"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"0.96"},{"groupId":"OG001","value":"-0.5","spread":"0.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"1.12"},{"groupId":"OG001","value":"-0.9","spread":"1.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"1.10"},{"groupId":"OG001","value":"-0.7","spread":"1.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"0.84"},{"groupId":"OG001","value":"-0.3","spread":"0.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"0.70"},{"groupId":"OG001","value":"-0.3","spread":"0.76"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"0.95"},{"groupId":"OG001","value":"-0.4","spread":"0.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"1.18"},{"groupId":"OG001","value":"-0.8","spread":"1.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.7","spread":"1.08"},{"groupId":"OG001","value":"-0.6","spread":"1.16"}]}]}]},{"type":"SECONDARY","title":"Change in Health Assessment Questionnaire-Disability Index (HAQ-DI)","description":"HAQ-DI - Scales for each question range from 0-3 (0=without any difficulty; 1=with some difficulty; 2=with much difficulty; 3=Unable to do). The \"total\" for each category is determined by the highest score (greatest difficulty) for that category. The score for the disability index is the mean of the eight category scores. If more than 2 of the categories or 25% are missing, the scale won't be scored. If fewer than 2 or the categories are missing, the sum of the categories was divided by the number of answered categories.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"0.59"},{"groupId":"OG001","value":"-0.4","spread":"0.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.4","spread":"0.75"},{"groupId":"OG001","value":"-0.5","spread":"0.42"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"0.69"},{"groupId":"OG001","value":"-0.4","spread":"0.59"}]}]}]},{"type":"SECONDARY","title":"Change in Highly Sensitive C-reactive Protein (Hs-CRP; mg/L)","description":"Change in highly sensitive C-reactive protein (hs-CRP; mg/L) from baseline to Weeks 12, 24, and 48 for subjects with PsA (Psoriatic arthritis) only.\n\nHighly sensitive C-reactive protein For subjects with PsA, change in hs-CRP from baseline to Weeks 12, 24, and 48 was assessed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.8","spread":"29.80"},{"groupId":"OG001","value":"6.2","spread":"8.39"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.9","spread":"32.10"},{"groupId":"OG001","value":"-3.3","spread":"6.63"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.1","spread":"31.98"},{"groupId":"OG001","value":"-1.3","spread":"9.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.2","spread":"33.69"},{"groupId":"OG001","value":"-2.8","spread":"6.01"}]}]}]},{"type":"SECONDARY","title":"The Proportion of Subjects With a Durability of Response at Week 48","description":"The proportion of subjects with a durability of response during Part 2. Durability of response was defined as the maintenance of the PASI-50 or greater at Weeks 24, 36, and 48 when compared to baseline (Week 0).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null},{"groupId":"OG001","value":"77.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"23","spread":null},{"groupId":"OG001","value":"22.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":10,"n":260},"commonTop":["Nasopharyngitis","Injection Site Reaction","Upper Respiratory Infection","Hypertension","Psoriasis"]}}}